Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Executive Summary
Corixa and GlaxoSmithKline will conduct a head-to-head study of their non-Hodgkin's lymphoma treatment Bexxar and Idec's Zevalin, Corixa told FDA's Oncologic Drugs Advisory Committee Dec. 17
You may also be interested in...
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin
Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies
Corixa will examine the retreatment effects of Bexxar patients who have had a duration of response against non-Hodgkin's lymphoma of at least six months as part of its Phase IV commitments for the oncologic
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GlaxoSmithKline and Corixa's Bexxar nuclear pharmacy training program could help encourage faster uptake of the oncologic than Idec's Zevalin